Biotech Business - June 10, 2020
Ilya Pharma awarded 5.3 million EUR
Ilya Pharma has secured a total of 5.3 million EUR in funding from the European Innovation Council (EIC) Accelerator program of blended financing. The funds will enable Ilya Pharma to accelerate a Phase II Trial of its lead drug candidate ILP100 which has the potential to heal problematic non-healing wounds in diabetes, potentially up to […]
Financing - June 1, 2020
“Aim high and build a strong team”
Jonas Jendi is an Investment Manager within the life science sector at Industrifonden, an evergreen venture capital fund, based in Stockholm, focusing on early-stage companies within life science and technology. In the current life science portfolio he is responsible for Nuevolution, Smartfish and Airsonett. What kind of companies are you and your colleagues focusing your […]
Biotech Business - May 21, 2020
Xbrane raises 146 million SEK
The Board of Directors of Xbrane Biopharma has successfully completed a directed issue of 3,853,799 shares corresponding to approximately SEK 146 million before costs related to the transaction. The subscription price in the Directed Share Issue has been determined to 38 SEK per share through an accelerated book building procedure performed by Vator Securities AB. […]
Financing - May 20, 2020
Oncoinvent secures 40 million NOK
Oncoinvent has completed a 40 million NOK round of financing, led by Hadean Ventures and with participation from existing investors CGS Holding AS, Helene Sundt AS, Alpine Capital AS, Artal AS, and Sciencons AS. The investment brings Oncoinvent’s total funding to 268 million NOK and will help the company pursue clinical development of its lead […]
Financing - April 24, 2020
Bio-Me receives 2 million EUR in public funding
Bio-Me has received a total of 2 million EUR in grants and public support from the Norwegian Research Council to develop a companion diagnostic test for immune checkpoint inhibitor (ICI) cancer treatments. Bio-Me will use its PMP – Precision Microbiome Profiling technology – to develop a microbiome-based test that can identify responders to ICI. Test […]
Financing - April 22, 2020
Pioneering synthetic biology company secures financial and strategic support
Swedish EnginZyme has announced a Series A investment of 6.4 million EUR led by Sofinnova Partners. The funds will be used to accelerate the development of the company’s technology platform and take its first internal production process to pilot, it states. A cell-free synthetic biology platform The chemistry industry has a central role to play […]
